291 related articles for article (PubMed ID: 23485939)
21. Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir.
Choe WH; Hong SP; Kim BK; Ko SY; Jung YK; Kim JH; Yeon JE; Byun KS; Kim KH; Ji SI; Kim SO; Lee CH; Kwon SY
Antivir Ther; 2009; 14(7):985-93. PubMed ID: 19918102
[TBL] [Abstract][Full Text] [Related]
22. Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus: virological breakthrough is also dependent on adherence to medication.
Kamezaki H; Kanda T; Wu S; Nakamoto S; Arai M; Maruyama H; Fujiwara K; Imazeki F; Yokosuka O
Scand J Gastroenterol; 2011 Sep; 46(9):1111-7. PubMed ID: 21623676
[TBL] [Abstract][Full Text] [Related]
23. Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy.
Reijnders JG; Pas SD; Schutten M; de Man RA; Janssen HL
J Hepatol; 2009 Apr; 50(4):674-83. PubMed ID: 19231002
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of entecavir in clinical practice in treatment-naive Caucasian chronic hepatitis B patients.
Buti M; Morillas RM; Prieto M; Diago M; Pérez J; Solà R; Bonet L; Palau A; Testillano M; García-Samaniego J; Rodríguez M;
Eur J Gastroenterol Hepatol; 2012 May; 24(5):535-42. PubMed ID: 22382708
[TBL] [Abstract][Full Text] [Related]
25. Antiviral resistance mutations and genotype-associated amino acid substitutions in treatment-naïve hepatitis B virus-infected individuals from the Indian subcontinent.
Ismail AM; Samuel P; Eapen CE; Kannangai R; Abraham P
Intervirology; 2012; 55(1):36-44. PubMed ID: 21311172
[TBL] [Abstract][Full Text] [Related]
26. Effect of hepatitis B virus reverse transcriptase variations on entecavir treatment response.
Wong DK; Kopaniszen M; Omagari K; Tanaka Y; Fong DY; Seto WK; Fung J; Huang FY; Zhang AY; Hung IF; Lai CL; Yuen MF
J Infect Dis; 2014 Sep; 210(5):701-7. PubMed ID: 24610871
[TBL] [Abstract][Full Text] [Related]
27. Clonal analysis of the quasispecies of antiviral-resistant HBV genomes in patients with entecavir resistance during rescue treatment and successful treatment of entecavir resistance with tenofovir.
Karatayli E; Idilman R; Karatayli SC; Cevik E; Yakut M; Seven G; Kabaçam G; Bozdayi AM; Yurdaydin C
Antivir Ther; 2013; 18(1):77-85. PubMed ID: 22878399
[TBL] [Abstract][Full Text] [Related]
28. Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs.
Salpini R; Svicher V; Cento V; Gori C; Bertoli A; Scopelliti F; Micheli V; Cappiello T; Spanò A; Rizzardini G; De Sanctis GM; Sarrecchia C; Angelico M; Perno CF
Antiviral Res; 2011 Nov; 92(2):382-5. PubMed ID: 21920388
[TBL] [Abstract][Full Text] [Related]
29. Entecavir plus adefovir combination treatment for chronic hepatitis B patients after failure of nucleoside/nucleotide analogues.
Lim YS; Lee TH; Heo NY; Shim JH; Lee HC; Suh DJ
Antivir Ther; 2012; 17(1):53-60. PubMed ID: 22267469
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients.
Suzuki F; Toyoda J; Katano Y; Sata M; Moriyama M; Imazeki F; Kage M; Seriu T; Omata M; Kumada H
J Gastroenterol Hepatol; 2008 Sep; 23(9):1320-6. PubMed ID: 18554238
[TBL] [Abstract][Full Text] [Related]
31. First-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment.
Ozaras R; Mete B; Ceylan B; Ozgunes N; Gunduz A; Karaosmanoglu H; Cagatay A; Gokturk K; Erdem L; Kocak F; Senates E; Tabak F
Eur J Gastroenterol Hepatol; 2014 Jul; 26(7):774-80. PubMed ID: 24901822
[TBL] [Abstract][Full Text] [Related]
32. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
Amini-Bavil-Olyaee S; Herbers U; Luedde T; Trautwein C; Tacke F
J Viral Hepat; 2011 Nov; 18(11):804-14. PubMed ID: 20887378
[TBL] [Abstract][Full Text] [Related]
33. Clinical and virological response to entecavir in HBV-related chronic hepatitis or cirrhosis: data from the clinical practice in a single-centre cohort.
Marengo A; Bitetto D; D'Avolio A; Ciancio A; Fabris C; Marietti M; Toniutto P; Di Perri G; Rizzetto M; Marzano A
Antivir Ther; 2013; 18(1):87-94. PubMed ID: 22872649
[TBL] [Abstract][Full Text] [Related]
34. Multidrug-resistant hepatitis B virus resulting from sequential monotherapy with lamivudine, adefovir, and entecavir: clonal evolution during lamivudine plus adefovir therapy.
Kim SS; Cho SW; Kim SO; Hong SP; Cheong JY
J Med Virol; 2013 Jan; 85(1):55-64. PubMed ID: 23096938
[TBL] [Abstract][Full Text] [Related]
35. Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-naive patients.
Jardi R; Rodriguez-Frias F; Schaper M; Ruiz G; Elefsiniotis I; Esteban R; Buti M
J Viral Hepat; 2007 Dec; 14(12):835-40. PubMed ID: 18070286
[TBL] [Abstract][Full Text] [Related]
36. Variability in the Responses of Hepatitis B Virus D-Subgenotypes to Antiviral Therapy: Designing Pan-D-Subgenotypic Reverse Transcriptase Inhibitors.
Khatun M; Kumar K; Baidya A; Mondal RK; Baszczyňski O; Kalčic F; Banerjee S; Dhali GK; Das K; Chowdhury A; Janeba Z; Chakrabarti S; Datta S
J Virol; 2022 Jan; 96(2):e0180021. PubMed ID: 34730399
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study.
Liaw YF; Raptopoulou-Gigi M; Cheinquer H; Sarin SK; Tanwandee T; Leung N; Peng CY; Myers RP; Brown RS; Jeffers L; Tsai N; Bialkowska J; Tang S; Beebe S; Cooney E
Hepatology; 2011 Jul; 54(1):91-100. PubMed ID: 21503940
[TBL] [Abstract][Full Text] [Related]
38. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation.
Fung J; Cheung C; Chan SC; Yuen MF; Chok KS; Sharr W; Dai WC; Chan AC; Cheung TT; Tsang S; Lam B; Lai CL; Lo CM
Gastroenterology; 2011 Oct; 141(4):1212-9. PubMed ID: 21762659
[TBL] [Abstract][Full Text] [Related]
39. Baseline Hepatitis B Virus DNA Level is a Promising Factor for Predicting the 3 (rd) Month Virological Response to Entecavir Therapy: A Study of Strict Defined Hepatitis B virus Induced Cirrhosis.
Xu Y; Wu XN; Shi YW; Wei W; Yang AT; Sun YM; Zhao WS; You H
Chin Med J (Engl); 2015 Jul; 128(14):1867-72. PubMed ID: 26168824
[TBL] [Abstract][Full Text] [Related]
40. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks.
Sherman M; Yurdaydin C; Simsek H; Silva M; Liaw YF; Rustgi VK; Sette H; Tsai N; Tenney DJ; Vaughan J; Kreter B; Hindes R;
Hepatology; 2008 Jul; 48(1):99-108. PubMed ID: 18537189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]